Headlines about Revance Therapeutics (NASDAQ:RVNC) have trended positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Revance Therapeutics earned a coverage optimism score of 0.41 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 88 out of 100, meaning that recent news coverage is very likely to have an effect on the stock’s share price in the near term.
Shares of Revance Therapeutics (NASDAQ RVNC) traded up 0.39% during trading on Wednesday, hitting $25.95. 5,899 shares of the stock were exchanged. The stock’s market cap is $785.58 million. Revance Therapeutics has a 12-month low of $12.35 and a 12-month high of $26.10. The stock’s 50 day moving average is $21.94 and its 200-day moving average is $20.76.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.10. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.07 million. Revance Therapeutics had a negative return on equity of 50.01% and a negative net margin of 32,179.33%. Revance Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.71) earnings per share. Equities research analysts anticipate that Revance Therapeutics will post ($3.92) EPS for the current year.
A number of brokerages have recently commented on RVNC. Aegis reissued a “buy” rating and issued a $36.00 target price on shares of Revance Therapeutics in a research note on Thursday, June 8th. ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 1st.
COPYRIGHT VIOLATION WARNING: “Revance Therapeutics (RVNC) Receives Daily Media Sentiment Score of 0.41” was reported by Mideast Time and is the property of of Mideast Time. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.mideasttime.com/revance-therapeutics-rvnc-receives-daily-media-sentiment-score-of-0-41/1817084.html.
In other Revance Therapeutics news, CEO L Daniel Browne sold 19,713 shares of the business’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $20.35, for a total value of $401,159.55. Following the sale, the chief executive officer now owns 183,932 shares of the company’s stock, valued at approximately $3,743,016.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Lauren P. Silvernail sold 1,793 shares of the business’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $20.20, for a total transaction of $36,218.60. Following the completion of the sale, the chief financial officer now directly owns 36,566 shares in the company, valued at approximately $738,633.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,793 shares of company stock valued at $685,576. Corporate insiders own 18.86% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.